NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on the benefits of NGS in oncology.
- Additional experts such as Mark Agulnik, MD, Mrinal M. Guckerman, DO, and Daniel Lefler, MD, contribute to the discussion.
- Other notable experts include Naval G. Daver, MD, Jessica Altman, MD, and Amir T. F. Roboz, MD.
No direct quotes are available in the provided text.
Author's summary: NGS improves biomarker testing in solid tumors.